Effect on Metabolic Parameters of Abilify in SPR

The Effects of Metabolic Parameters of Aripiprazole in Patients With Schizophrenia

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00569764

Enrollment

100

Registered

2007-12-07

Start date

2007-12-31

Completion date

2009-10-31

Last updated

2009-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Syndrome, Schizophrenia

Keywords

schizophrenia, metabolic syndrome, aripiprazole

Brief summary

To measure the long-term changes in weight and plasma lipids after switching antipsychotic treatment to aripiprazole

Detailed description

To measure the long-term changes in weight, plasma lipids and fasting blood glucose after switching antipsychotic treatment to aripiprazole, 1 year, open label studies in out and in-patients with schizophrenia. The measurement of weight and lipid profile and fasting blood glucose will be measured at baseline and every 3 months for 1 year.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* DSM-IV diagnosis with schizophrenia * who signed an informed consent

Exclusion criteria

* comorbid with substance abuse or substance dependence * pregnancy or lactation

Design outcomes

Primary

Measure	Time frame
weight lipid profile : HDL, LDL, total-cholesterol, triglyceride fasting blood glucose	1 year

Secondary

Measure	Time frame
prolactin ECG	1 year

Countries

South Korea

Contacts

Primary ContactShi Hyun Kang, MD

drshe@hanmail.net82-2-2204-0326

Outcome results